BioSpace News Archive

Mentice AB announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson.

BioVie Inc. announced that the Company’s Phase 2 trial assessing NE3107’s potential pro-motoric impact in Parkinson’s disease has fully enrolled 44 patients.

Jazz Pharmaceuticals plc and Zymeworks Inc. announced that Jazz and Zymeworks’ subsidiary, Zymeworks BC Inc., have entered into an exclusive licensing agreement under which Jazz will acquire development and commercialization rights to Zymeworks’ zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia/Pacific territories previously licensed by Zymeworks.

Inversago Pharma Inc. announced the appointment of two new board members: Ed Mathers, BSc, General Partner at New Enterprise Associates and Nanna Lüneborg, PhD, MBA, General Partner at Forbion.

Triumvira Immunologics announced a multi-year agreement with AmplifyBio to use its facilities in South San Francisco, Calif.

Zymeworks Inc. announced that management will host a conference call and webcast to discuss Zymeworks has entered into an exclusive licensing agreement for zanidatamab, a HER2-targeted bispecific antibody developed using Zymeworks’ proprietary Azymetric™ platform, with Jazz Pharmaceuticals plc.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced it will report third quarter 2022 financial results on Tuesday, November 8, 2022, before the U.S. financial markets open.

Ayala Pharmaceuticals, Inc. and Advaxis, Inc. announced that they have entered into a definitive merger agreement.

ViewRay, Inc. announced that the company’s MRIdian® MRI-Guided Radiation Therapy System will be featured at the 64th Annual Meeting of the American Society for Radiation Oncology, being held October 23-26, 2022, at the Henry B. González Convention Center in San Antonio, Texas.

KalVista Pharmaceuticals, Inc. announced the publication of new sebetralstat data in both the Journal of Medicinal Chemistry and Xenobiotica.